Zacks Investment Research Upgrades Autolus Therapeutics (NASDAQ:AUTL) to Hold

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “

Other equities analysts have also issued research reports about the stock. HC Wainwright set a $18.00 price objective on shares of Sutro Biopharma and gave the company a “buy” rating in a research report on Friday, May 17th. William Blair initiated coverage on shares of American Software in a research report on Wednesday, April 3rd. They set an “outperform” rating and a $12.03 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $42.67.

Shares of NASDAQ AUTL traded down $0.08 during mid-day trading on Thursday, reaching $16.01. The company had a trading volume of 1,306 shares, compared to its average volume of 95,644. The business has a fifty day simple moving average of $17.38. The company has a quick ratio of 10.66, a current ratio of 10.66 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $684.16 million and a P/E ratio of -11.27. Autolus Therapeutics has a 12-month low of $14.80 and a 12-month high of $53.24.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.11). The firm had revenue of $1.96 million for the quarter, compared to analyst estimates of $0.30 million. Research analysts expect that Autolus Therapeutics will post -3.07 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of Autolus Therapeutics by 4,011.3% in the fourth quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock worth $6,666,000 after acquiring an additional 198,036 shares during the last quarter. CWM LLC acquired a new stake in shares of Autolus Therapeutics in the first quarter worth $1,105,000. Marshall Wace LLP grew its stake in shares of Autolus Therapeutics by 93.4% in the first quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock worth $7,330,000 after acquiring an additional 112,489 shares during the last quarter. Barclays PLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $113,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $322,000. 43.37% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.